Histogenics (HSGX) Tops Q3 EPS by 5c

Histogenics (NASDAQ: HSGX) reported Q3 EPS of ($0.23), $0.05 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Histogenics (HSGX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c
• Cheetah Net Supply Chain Service Inc. (CTNT) Reports Q2 EPS of $0.04